A Phase 3 interventional study of Orforglipron and Semaglutide in Type 2 Diabetes, sponsored by Eli Lilly and Company. Completed at 131 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies testing orforglipron in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, 4 of them phase 3. orforglipron · Diabetes Mellitus, Type 2.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, this one is the 2nd largest by enrollment, is one of 6 that started in 2023, is one of 11 in phase 3, and was the 8th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 15 studies testing orforglipron in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in India, Saudi Arabia, South Africa and 1 more country
Ages 18–65
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 8 more countries
Ages 10–17
Massachusetts General Hospital
Ages 18–79
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
15 studies; the count open now beside each. This study's row is marked.
First in 2020; this study’s year is marked. 6 started in 2023.
This study's enrollment of 1,698 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 546 across the 15 interventional studies. Of the 10 that completed or were terminated, 9 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 15 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company: 10 open now, 21 under way, 11 of them phase 3. Of 211 finished, 155 (73%) have results posted.
Among the 238 studies in Diabetes Mellitus, Type 2 by Eli Lilly and Company, this one is the 10th largest by enrollment of the 232 interventional ones that give a count, is one of 17 that started in 2023, is one of 85 in phase 3, and was the 203rd registered.
Eli Lilly and Company’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
3 of the studies testing orforglipron in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613307Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting | 2027-05 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 15 studies testing orforglipron in Diabetes Mellitus, Type 2, from their registry updates:
Among Eli Lilly and Company’s 238 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants initiated treatment with a 1 mg once-daily oral dose of orforglipron and increased the dose every 4 weeks until the targeted dose of 12 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.
Drug: Orforglipron
Participants initiated treatment with a 1 mg once-daily oral dose of orforglipron and increased the dose every 4 weeks until the targeted dose of 36 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.
Drug: Orforglipron
Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 7 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.
Drug: Semaglutide
Participants initiated treatment with a 3 mg once-daily oral dose of semaglutide and increased the dose every 4 weeks until the targeted dose of 14 mg once-daily was reached, after which this dose was to be continued for the remainder of the 52-week treatment period.
Drug: Semaglutide
Administered orally
Also known as: LY3502970
Administered orally
Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide]
* HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 12 mg Orforglipron Versus 14 mg Semaglutide, Superiority of 12 mg and 36 mg Orforglipron Versus 7 mg and 14 mg Semaglutide]
* HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percentage of Participants Who Achieved HbA1c <7.0% [53 Millimoles/Mole (mmol/Mol)]
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
Time frame: Week 52
Percentage of Participants Who Achieved HbA1c <=6.5% (48 mmol/Mol)
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
Time frame: Week 52
Percentage of Participants Who Achieved HbA1c <5.7% (39 mmol/Mol)
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
Time frame: Week 52
Percent Change From Baseline in Body Weight
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Change From Baseline in Body Weight
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Change From Baseline in Fasting Serum Glucose
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG)
The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percentage of Participants Who Achieved Weight Loss of >=5%
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
Time frame: Week 52
Percentage of Participants Who Achieved Weight Loss of >=10%
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
Time frame: Week 52
Percentage of Participants Who Achieved Weight Loss of >=15%
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
Time frame: Week 52
Change From Baseline in Systolic Blood Pressure (SBP)
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Change From Baseline in Diastolic Blood Pressure (DBP)
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percent Change From Baseline in Total Serum Cholesterol
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percent Change From Baseline in Serum Low Density Lipoprotein (LDL) Cholesterol
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percent Change From Baseline in Serum Non High Density Lipoprotein (Non-HDL) Cholesterol
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percent Change From Baseline in Serum Triglycerides
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percent Change From Baseline in Serum High Density Lipoprotein (HDL) Cholesterol
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Percent Change From Baseline in Serum Very Low Density Lipoprotein (VLDL) Cholesterol
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
Time frame: Baseline, Week 52
Change From Baseline in Short Form 36 Version 2 (SF-36-v2) Acute Form (Physical Component and Mental Component Scores)
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the physical component summary and mental component summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
Time frame: Baseline, Week 52
| Milestone | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Started | 424 | 423 | 426 | 425 |
| Received at least one dose of study drug | 424 | 423 | 426 | 425 |
| Completed | 382 | 380 | 388 | 401 |
| Not completed | 42 | 43 | 38 | 24 |
| Withdrew: Adverse event | 7 | 4 | 4 | 5 |
| Withdrew: Withdrawal by subject | 19 | 22 | 16 | 10 |
| Withdrew: Lost to follow-up | 9 | 10 | 9 | 3 |
| Withdrew: Physician decision | 1 | 1 | 1 | 3 |
| Withdrew: Death | 1 | 1 | 2 | 0 |
| Withdrew: Non-compliance with study drug | 2 | 0 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 1 | 0 | 1 | 0 |
| Withdrew: Other - as reported by the investigator | 2 | 3 | 5 | 3 |
* HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percentage of HbA1c | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 36 mg Orforglipron Versus 14 mg Semaglutide and 12 mg Orforglipron Versus 7 mg Semaglutide] | -1.91 ± 0.058 | -2.16 ± 0.051 | -1.11 ± 0.063 | -1.45 ± 0.061 |
* HbA1c is the glycosylated fraction of hemoglobin A. It is measured to identify average plasma glucose concentration over prolonged periods of time. * LS mean was analysed by mixed model repeated measures (MMRM) model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percentage of HbA1c | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) [Non-inferiority of 12 mg Orforglipron Versus 14 mg Semaglutide, Superiority of 12 mg and 36 mg Orforglipron Versus 7 mg and 14 mg Semaglutide] | -1.91 ± 0.058 | -2.16 ± 0.051 | -1.11 ± 0.063 | -1.45 ± 0.061 |
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
| percentage of participants | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c <7.0% [53 Millimoles/Mole (mmol/Mol)] | 80.04 ± 1.97 | 85.41 ± 1.80 | 54.63 ± 2.45 | 66.12 ± 2.27 |
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
| percentage of participants | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c <=6.5% (48 mmol/Mol) | 71.76 ± 2.26 | 76.82 ± 2.14 | 40.87 ± 2.38 | 50.88 ± 2.42 |
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
| percentage of participants | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percentage of Participants Who Achieved HbA1c <5.7% (39 mmol/Mol) | 25.44 ± 2.24 | 37.09 ± 2.56 | 7.84 ± 1.27 | 12.54 ± 1.64 |
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Body Weight | -6.7 ± 0.34 | -9.2 ± 0.40 | -3.7 ± 0.27 | -5.3 ± 0.30 |
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| kilogram (kg) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Body Weight | -6.6 ± 0.34 | -8.9 ± 0.39 | -3.6 ± 0.26 | -5.0 ± 0.29 |
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| milligram per deciliter (mg/dL) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Fasting Serum Glucose | -55.2 ± 1.77 | -60.1 ± 1.55 | -28.9 ± 2.49 | -40.2 ± 2.33 |
The SMBG data were collected at the following 7 time points: Morning Premeal - Fasting, Morning 2-hour Post meal, Midday Premeal, Midday 2-hour Post meal, Evening Premeal, Evening 2-hour Post meal and Bedtime. The daily average was calculated as the average of the 7 blood glucose values collected on a particular day. LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| milligram per deciliter (mg/dL) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Daily Average 7-point Self-monitored Blood Glucose (SMBG) | -69.4 ± 1.60 | -74.9 ± 1.40 | -51.2 ± 2.10 | -61.4 ± 1.48 |
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
| percentage of participants | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss of >=5% | 59.18 ± 2.55 | 69.49 ± 2.39 | 36.89 ± 2.53 | 49.39 ± 2.57 |
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
| percentage of participants | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss of >=10% | 28.23 ± 2.34 | 43.46 ± 2.54 | 13.18 ± 1.84 | 20.95 ± 2.08 |
The reported values represent model-based group mean percentages estimated from a logistic regression model using imputed data, with estimates combined across multiple imputations using Rubin's rule. Logistic regression model variables: Country + Treatment\*Baseline + Treatment\*Strata (defined by baseline HbA1c level \[\<=8.0%, \>8.0%\]).
| percentage of participants | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percentage of Participants Who Achieved Weight Loss of >=15% | 11.99 ± 1.65 | 23.21 ± 2.17 | 4.99 ± 1.19 | 6.45 ± 1.25 |
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| millimeters of mercury (mmHg) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Systolic Blood Pressure (SBP) | -4.5 ± 0.55 | -5.4 ± 0.65 | -2.0 ± 0.58 | -2.7 ± 0.59 |
LS mean was analysed by MMRM model with Country + Baseline\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| millimeters of mercury (mmHg) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Change From Baseline in Diastolic Blood Pressure (DBP) | -0.6 ± 0.39 | 0.0 ± 0.42 | -0.4 ± 0.39 | -0.3 ± 0.39 |
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Total Serum Cholesterol | -4.25 ± 0.928 | -2.93 ± 0.920 | -0.50 ± 1.149 | 0.19 ± 0.927 |
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Serum Low Density Lipoprotein (LDL) Cholesterol | -4.32 ± 1.643 | -1.93 ± 1.568 | -2.49 ± 1.635 | 1.95 ± 1.753 |
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Serum Non High Density Lipoprotein (Non-HDL) Cholesterol | -7.70 ± 1.213 | -5.48 ± 1.225 | -2.11 ± 1.451 | -1.93 ± 1.245 |
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Serum Triglycerides | -16.89 ± 1.698 | -15.95 ± 1.688 | -4.98 ± 2.270 | -13.44 ± 1.681 |
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Serum High Density Lipoprotein (HDL) Cholesterol | 6.78 ± 0.852 | 5.40 ± 0.880 | 3.86 ± 1.057 | 6.33 ± 1.020 |
LS mean was analysed by MMRM model with Country + log(Baseline)\*Time\*Treatment + Strata\*Time\*Treatment as variables. Strata is defined by joint levels of HbA1c level (\<=8.0%, \>8.0%).
| Percent change | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Percent Change From Baseline in Serum Very Low Density Lipoprotein (VLDL) Cholesterol | -14.87 ± 1.651 | -14.79 ± 1.603 | -5.44 ± 1.771 | -12.52 ± 1.647 |
The SF-36v2 is a participant-reported measure designed to assess health status using 36 items across 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. The physical functioning domain assesses limitations due to health "now," whereas the remaining domains assess functioning "in the past week." Each domain is scored individually, and information from these 8 domains is aggregated into 2 health component summary scores, the physical component summary and mental component summary. Items are answered on Likert scales of varying lengths (3-point, 5-point, or 6-point scales). Scoring of each domain and both summary scores are norm based and presented in the form of T-scores, with a mean of 50 and a standard deviation of 10. Higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores.
| T-score | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Physical Component Score | 2.88 ± 0.333 | 2.57 ± 0.328 | 2.89 ± 0.322 | 2.56 ± 0.324 |
| Mental Component Score | 1.32 ± 0.401 | 0.89 ± 0.438 | 1.13 ± 0.415 | 0.65 ± 0.437 |
Collected over Baseline to end of safety follow-up (up to 57 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 12 mg Orforglipron | 1/424 (0.2%) | 21/424 (5%) | 278/424 (65.6%) |
| 36 mg Orforglipron | 1/423 (0.2%) | 40/423 (9.5%) | 278/423 (65.7%) |
| 7 mg Semaglutide | 2/426 (0.5%) | 19/426 (4.5%) | 225/426 (52.8%) |
| 14 mg Semaglutide | 0/425 (0%) | 24/425 (5.6%) | 249/425 (58.6%) |
| Event | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| Uterine cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/195 | 0/218 | 0/206 | 1/206 |
| Abdominal painGastrointestinal disorders | 1/424 | 2/423 | 0/426 | 0/425 |
| AppendicitisInfections and infestations | 1/424 | 2/423 | 0/426 | 0/425 |
| PneumoniaInfections and infestations | 0/424 | 2/423 | 2/426 | 1/425 |
| Ischaemic strokeNervous system disorders | 2/424 | 0/423 | 1/426 | 2/425 |
| Acute myocardial infarctionCardiac disorders | 0/424 | 0/423 | 2/426 | 1/425 |
| HypertensionVascular disorders | 0/424 | 0/423 | 2/426 | 0/425 |
| Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/195 | 1/218 | 0/206 | 0/206 |
| Endometrial cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/195 | 1/218 | 0/206 | 0/206 |
| Angina pectorisCardiac disorders | 0/424 | 1/423 | 0/426 | 0/425 |
| Event | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 112/424 | 116/423 | 56/426 | 90/425 |
| DiarrhoeaGastrointestinal disorders | 92/424 | 99/423 | 56/426 | 77/425 |
| VomitingGastrointestinal disorders | 72/424 | 70/423 | 33/426 | 44/425 |
| HyperglycaemiaMetabolism and nutrition disorders | 25/424 | 20/423 | 69/426 | 34/425 |
| Diabetic retinopathyEye disorders | 57/424 | 60/423 | 54/426 | 58/425 |
| ConstipationGastrointestinal disorders | 56/424 | 55/423 | 33/426 | 38/425 |
| DyspepsiaGastrointestinal disorders | 48/424 | 44/423 | 18/426 | 33/425 |
| EructationGastrointestinal disorders | 42/424 | 32/423 | 17/426 | 14/425 |
| Abdominal distensionGastrointestinal disorders | 24/424 | 34/423 | 11/426 | 14/425 |
| Decreased appetiteMetabolism and nutrition disorders | 30/424 | 29/423 | 21/426 | 27/425 |
All randomised participants.
| Age, Continuous(years) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide | Total |
|---|---|---|---|---|---|
| Mean | 54.0 ± 11.3 | 53.4 ± 11.4 | 54.9 ± 11.2 | 53.4 ± 10.5 | 53.9 ± 11.1 |
| Sex: Female, Male(Participants) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide | Total |
|---|---|---|---|---|---|
| Female | 195 | 218 | 206 | 206 | 825 |
| Male | 229 | 205 | 220 | 219 | 873 |
| Ethnicity (NIH/OMB)(Participants) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 304 | 304 | 316 | 310 | 1234 |
| Not Hispanic or Latino | 117 | 117 | 108 | 113 | 455 |
| Unknown or Not Reported | 3 | 2 | 2 | 2 | 9 |
| Race (NIH/OMB)(Participants) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 90 | 79 | 76 | 89 | 334 |
| Asian | 50 | 51 | 52 | 49 | 202 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 17 | 16 | 12 | 20 | 65 |
| White | 250 | 259 | 266 | 254 | 1029 |
| More than one race | 11 | 10 | 13 | 8 | 42 |
| Unknown or Not Reported | 6 | 8 | 7 | 5 | 26 |
| Region of Enrollment(Participants) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide | Total |
|---|---|---|---|---|---|
| Argentina | 145 | 145 | 146 | 146 | 582 |
| China | 26 | 25 | 26 | 25 | 102 |
| Japan | 20 | 20 | 21 | 21 | 82 |
| Mexico | 123 | 123 | 123 | 123 | 492 |
| United States | 110 | 110 | 110 | 110 | 440 |
| HemoglobinA1c (HbA1c)(Percentage of HbA1c) | 12 mg Orforglipron | 36 mg Orforglipron | 7 mg Semaglutide | 14 mg Semaglutide | Total |
|---|---|---|---|---|---|
| Mean | 8.27 ± 1.05 | 8.28 ± 1.11 | 8.31 ± 1.09 | 8.30 ± 1.12 | 8.29 ± 1.09 |
Showing the first 100 of 131 sites across 6 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Sep 2023 to primary completion in Aug 2025, 23 months.
Results were first posted in Sep 2026, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 23 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron